Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has released its 2025 Corporate Sustainability Report, highlighting significant progress in environmental stewardship and innovation. The company achieved a notable 40% reduction in Scope 1 and 2 emissions through renewable electricity adoption at its Minneapolis headquarters.
Under CEO Kim Kelderman's leadership, Bio-Techne has committed to setting science-based GHG reduction targets for validation by SBTi in 2026. The company continues to advance breakthroughs in various diseases while implementing enhanced governance measures, including new Board oversight of AI and completion of climate assessments.
The report emphasizes Bio-Techne's focus on sustainable innovation across its life sciences portfolio, particularly in cell therapy, proteomic instruments, and precision diagnostics.
Positive
- Achieved 40% reduction in Scope 1 and 2 emissions enterprise-wide
- Committed to science-based GHG reduction targets for validation by SBTi in 2026
- Implemented enhanced governance measures including AI oversight
- Continued development of breakthrough treatments for multiple diseases
Negative
- None.
News Market Reaction
On the day this news was published, TECH declined 3.21%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions
"As a global innovator in life sciences, our mission is to improve the quality of life by catalyzing advances in science and medicine," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We recognize that human health and the environment are intrinsically connected. By aligning our science with sustainable business practices, we not only unlock potential for better health outcomes, but also create lasting value for our employees, empower our customers, and strengthen the communities in which we live and work."
Highlights from Bio-Techne's 2025 Sustainability Report demonstrate measurable progress and bold commitments, including:
- Ongoing development and commercialization of breakthroughs in cancer, diabetes, neurodegenerative, autoimmune, and rare diseases—transforming diagnosis and care for millions worldwide.
- An estimated
40% reduction in Scope 1 and 2 emissions enterprise-wide, driven by the transition to100% renewable electricity at the company'sMinneapolis headquarters.⃰ - Commitment to set Scope 1, 2, and 3 greenhouse gas (GHG) reduction targets, with submission for validation to the Science Based Targets Initiative (SBTi) in 2026.
- Enhanced governance measures, including new Board oversight of artificial intelligence and completion of the first double materiality and climate assessments to guide sustainability priorities.
- Investment in culture and careers, with development and learning opportunities designed to empower teams under Bio-Techne's EPIC values—Empowerment, Passion, Innovation, and Collaboration
Bio-Techne's sustainability initiatives also fuel innovation across its life sciences portfolio, driving advances in cell therapy workflows, proteomic analytical instruments, spatial biology, and precision diagnostics—all developed with increased emphasis on efficiency and resource-conscious design.
"Our customers trust us to advance science responsibly, and we know that starts with our people," added Kelderman. "This report underscores our commitment to protecting the environment, supporting our employees and communities, and creating a workplace where diverse perspectives drive innovation and lasting impact."
The full 2025 Sustainability Report is available in the Corporate and Social Responsibility section of Bio-Techne's website.
*Based on Scope 1 and 2 market-based greenhouse gas emissions.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact:
Corporate Communications
media.relations@bio-techne.com
David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-highlights-progress-on-climate-innovation-and-culture-in-2025-sustainability-report-302565713.html
SOURCE Bio-Techne Corporation
FAQ
What environmental achievements did Bio-Techne (TECH) report in its 2025 Sustainability Report?
Who is the CEO of Bio-Techne (TECH) in 2025?
What governance changes did Bio-Techne (TECH) implement in 2025?
What are Bio-Techne's (TECH) key areas of innovation focus in 2025?
What are Bio-Techne's (TECH) EPIC values?
